Pertussis Vaccine Market Size, Share, Growth, and Industry Analysis, By Type (Acellular Vaccines, Whole-cell Vaccines), By Application (12 Months Below, 12 Months Above), Regional Insights and Forecast to 2035

Pertussis Vaccine Market Overview

The global Pertussis Vaccine Market is forecast to expand from USD 5558.62068 million in 2026 to USD 5705.93 million in 2027, and is expected to reach USD 7033.923200316 million by 2035, growing at a CAGR of 2.65% over the forecast period.

The Pertussis Vaccine Market is driven by rising global immunization programs, with over 116 million infants vaccinated annually through routine immunization programs. In 2023, pertussis vaccines were administered in more than 180 countries, ensuring 92% global coverage. Acellular pertussis vaccines accounted for 74% of doses delivered, while whole-cell pertussis vaccines represented 26%. More than 5.5 billion cumulative doses have been distributed worldwide since the 1990s, significantly reducing disease burden. Asia-Pacific leads with 43% of total vaccinations, followed by Africa with 26%, Europe with 18%, and the Americas with 13%. This reflects both strong adoption and ongoing immunization commitments.

In the United States, the Pertussis Vaccine Market is supported by nearly 3.7 million annual births, with over 95% vaccination coverage among infants. More than 12 million doses of pertussis-containing vaccines were administered in 2023, including both DTaP and Tdap formulations. Around 81% of U.S. adolescents received booster doses, while 61% of pregnant women were immunized to provide neonatal protection. The U.S. accounted for 28% of vaccine demand across North America, supported by robust healthcare infrastructure and CDC-led immunization guidelines. With over 18,000 pertussis cases still reported annually, consistent vaccine demand underscores the importance of high coverage.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key findings

• Key Market Driver: Around 92% of infants globally receive pertussis vaccines, with 74% covered by acellular vaccines and 26% by whole-cell formulations, ensuring strong worldwide immunization coverage.
• Major Market Restraint: Nearly 38% of low-income countries still depend on whole-cell vaccines, facing 27% higher adverse reaction rates, limiting broader acceptance of modern vaccine alternatives.
• Emerging Trends: About 33% of new pertussis vaccine research focuses on maternal immunization, while 29% emphasizes next-generation combination vaccines targeting diphtheria, tetanus, and pertussis.
• Regional Leadership: Asia-Pacific accounts for 43% of global pertussis vaccinations, followed by Africa at 26%, Europe at 18%, and the Americas at 13% in 2023.
• Competitive Landscape: The top five vaccine manufacturers hold 61% of global supply, while over 25 regional producers provide the remaining 39%, ensuring broad production diversity.
• Market Segmentation: Acellular pertussis vaccines represent 74% of global demand, while whole-cell pertussis vaccines retain 26% market presence, largely in low- and middle-income countries.
• Recent Development: Between 2022 and 2023, more than 12 million maternal Tdap doses were administered worldwide, marking a 21% increase compared to the 2020 baseline.

Pertussis Vaccine Market Latest Trends

The Pertussis Vaccine Market has witnessed rapid transformation in recent years, with 74% of global immunizations now delivered using acellular vaccines. More than 116 million infants were immunized in 2023, marking a 4% increase compared to 2020. Maternal immunization programs expanded significantly, with 12 million women vaccinated during pregnancy worldwide in 2023, providing neonatal protection during the first months of life. Around 33% of ongoing clinical trials target new acellular vaccine formulations with improved safety and long-term immunity. Booster vaccine demand has surged, with 78% of adolescents in developed countries completing their Tdap schedule. Additionally, around 19% of countries integrated pertussis vaccines into adult immunization programs, compared to just 11% in 2015. Pertussis Vaccine Market Trends reflect rising emphasis on combination vaccines, with over 85% of immunization campaigns delivering DTaP formulations in 2023, making multi-antigen solutions the preferred choice globally.

Pertussis Vaccine Market Dynamics

DRIVER

"Rising global immunization programs and high coverage rates."

The Pertussis Vaccine Market is fueled by widespread adoption across over 180 countries, with global infant coverage reaching 92% in 2023. Around 116 million infants received pertussis vaccines annually, up from 110 million in 2020. Acellular vaccines dominated with 74% of doses, replacing older formulations in high-income countries. Routine immunization programs supported by organizations such as UNICEF and WHO distribute nearly 80 million doses annually to low- and middle-income nations. In the U.S., 95% of children under five are immunized, driving demand for 12 million doses annually. This strong international coverage underpins consistent growth in vaccine demand.

RESTRAINT

"Adverse events and public perception in low-income regions."

Despite broad adoption, the Pertussis Vaccine Market faces restraints due to higher adverse event rates with whole-cell vaccines, which still account for 26% of global doses. Around 27% of vaccinated children in low-income countries experience mild reactions, compared to just 12% with acellular versions. This has limited broader acceptance of pertussis vaccines in certain regions, particularly Africa and parts of Southeast Asia, where whole-cell vaccines dominate. Around 38% of low-income nations lack access to acellular vaccines due to higher costs. This gap in perception and affordability has restricted universal uptake, slowing overall immunization momentum in emerging markets.

OPPORTUNITY

"Expansion of maternal immunization programs."

A key opportunity for the Pertussis Vaccine Market is maternal immunization, which has grown by 21% since 2020. In 2023, more than 12 million pregnant women received Tdap vaccines globally, protecting newborns during early months. In the U.S., maternal vaccination coverage reached 61%, compared to just 44% in 2018. Europe reported 58% maternal coverage, while Latin America achieved 47%. Clinical evidence suggests maternal vaccination reduces neonatal pertussis risk by 78%, strengthening adoption. Around 33% of current research investments target maternal vaccines, highlighting this as a high-growth segment. Expanding maternal programs could add 20 million additional doses annually by 2030.

CHALLENGE

"Supply chain constraints and production capacity limitations."

The Pertussis Vaccine Market faces challenges from manufacturing bottlenecks and uneven distribution. Around 64% of global vaccine supply originates from five major companies, with Asia-Pacific and Europe housing most production facilities. During 2023, supply delays impacted 18% of African vaccination campaigns and 14% in Southeast Asia. Cold chain disruptions accounted for 21% of shipment delays, reducing vaccine potency in certain regions. Furthermore, rising demand for combination DTaP formulations has stretched production lines, with 12% of planned doses delayed in 2022–2023. These challenges underscore the need for investment in local production capacity and resilient logistics to maintain global vaccine coverage.

Pertussis Vaccine Market Segmentation 

The Pertussis Vaccine Market is segmented by type and application, reflecting distinct immunization strategies across global populations. By type, acellular vaccines dominate with broad adoption in high- and middle-income countries, while whole-cell vaccines maintain strong demand in low-income nations due to affordability. By application, vaccines are administered to children below 12 months, ensuring early-life immunity, and above 12 months, mainly as booster doses during childhood and adolescence. In 2023, over 116 million infants were immunized worldwide, with 74% receiving acellular formulations, while more than 92 million booster doses were delivered to children over 12 months, driving widespread coverage and global protection.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Acellular Vaccines: Acellular pertussis vaccines are the most widely used type, accounting for 74% of global doses administered in 2023, equal to nearly 86 million infant immunizations. These vaccines are preferred in developed regions such as North America and Europe, where more than 95% of children receive acellular formulations. In Asia-Pacific, acellular vaccines represent 62% of total pertussis immunizations, while in Latin America they cover 57% of the market. Acellular vaccines are associated with 12% adverse reaction rates compared to 27% with whole-cell, boosting demand in premium healthcare systems. Over 120 manufacturers globally produce acellular vaccines, highlighting broad supply chains.

The acellular vaccine segment has a market size of USD 2.8 billion, holding a 74% share, with a CAGR of 6.7% projected during the forecast period.

Top 5 Major Dominant Countries in the Acellular Vaccines Segment

• United States: Market size USD 0.9 billion, 28% share, CAGR 6.8%, with 12 million acellular doses administered annually across infant and adolescent schedules.
• Germany: Market size USD 0.3 billion, 9% share, CAGR 6.6%, with over 3.2 million acellular doses administered annually in both public and private programs.
• Japan: Market size USD 0.25 billion, 8% share, CAGR 6.5%, distributing nearly 2.8 million doses annually under strict national immunization guidelines.
• China: Market size USD 0.22 billion, 7% share, CAGR 6.9%, delivering more than 5 million acellular doses annually to infants in urban regions.
• United Kingdom: Market size USD 0.18 billion, 6% share, CAGR 6.6%, providing nearly 2.1 million acellular vaccine doses annually for infants and booster coverage.

Whole-cell Vaccines: Whole-cell pertussis vaccines account for 26% of global demand, with nearly 30 million doses administered in 2023. They remain critical in low-income regions such as Africa and South Asia due to affordability and local production. Around 38% of countries still use whole-cell vaccines exclusively, representing over 75 million cumulative doses distributed annually. Despite higher adverse event rates of 27%, these vaccines are valued for cost-effectiveness, priced nearly 45% lower than acellular alternatives. Over 40 countries continue manufacturing whole-cell vaccines domestically, ensuring supply to rural and low-income populations, where demand remains strong due to economic constraints.

The whole-cell vaccine segment has a market size of USD 0.9 billion, holding a 26% share, with a CAGR of 5.4% projected during the forecast period.

Top 5 Major Dominant Countries in the Whole-cell Vaccines Segment

• India: Market size USD 0.25 billion, 9% share, CAGR 5.5%, with over 11 million whole-cell doses distributed annually through public healthcare networks.
• Brazil: Market size USD 0.15 billion, 6% share, CAGR 5.3%, delivering nearly 6 million whole-cell doses annually to infants and young children.
• Nigeria: Market size USD 0.12 billion, 5% share, CAGR 5.2%, administering nearly 5 million doses in 2023, covering 70% of infants nationwide.
• Pakistan: Market size USD 0.1 billion, 4% share, CAGR 5.3%, distributing nearly 4 million whole-cell doses annually across rural and semi-urban regions.
• Bangladesh: Market size USD 0.08 billion, 3% share, CAGR 5.4%, with nearly 3 million doses administered annually under the Expanded Program on Immunization.

BY APPLICATION

12 Months Below: Infants under 12 months account for the largest share of pertussis vaccinations, with more than 116 million doses administered globally in 2023. Coverage rates exceed 95% in North America, 91% in Europe, and 87% in Asia-Pacific. In Africa, 76% of infants received their first pertussis immunization in 2023, reflecting gradual improvements. Around 74% of these vaccinations are acellular, while 26% are whole-cell. More than 180 countries include infant pertussis vaccination in their national immunization schedules, protecting newborns during the first year of life. The Pertussis Vaccine Market Report highlights this as the most critical application segment.

The below 12 months application segment has a market size of USD 2.9 billion, accounting for 78% global share, with a CAGR of 6.8% projected during the forecast period.

Top 5 Major Dominant Countries in the Below 12 Months Segment

• United States: Market size USD 0.8 billion, 28% share, CAGR 6.9%, with over 3.7 million infant doses administered annually through healthcare providers.
• China: Market size USD 0.4 billion, 14% share, CAGR 6.7%, distributing nearly 9 million infant doses annually in both urban and rural settings.
• India: Market size USD 0.3 billion, 10% share, CAGR 6.5%, delivering nearly 7 million doses annually under the public healthcare framework.
• Germany: Market size USD 0.22 billion, 8% share, CAGR 6.6%, administering nearly 2.5 million infant doses annually with high compliance rates.
• Brazil: Market size USD 0.18 billion, 6% share, CAGR 6.5%, distributing nearly 2.2 million doses annually as part of childhood immunization schedules.

12 Months Above: Children above 12 months, including adolescents and young adults, represent a vital booster dose segment. In 2023, more than 92 million booster doses were administered worldwide, with North America and Europe accounting for 61% of these. Adolescent coverage rates exceed 81% in the U.S., 79% in Germany, and 74% in the UK. Around 19% of booster coverage was reported in adults, reflecting expanding immunization guidelines. Booster shots are critical in maintaining herd immunity, with over 35 million adolescents receiving Tdap globally in 2023. Pertussis Vaccine Market Insights emphasize this segment as key to long-term immunity sustainability.

The above 12 months application segment has a market size of USD 0.8 billion, accounting for 22% global share, with a CAGR of 5.8% projected during the forecast period.

Top 5 Major Dominant Countries in the Above 12 Months Segment

• United States: Market size USD 0.25 billion, 31% share, CAGR 5.9%, with nearly 7 million adolescent and adult booster doses administered annually.
• Germany: Market size USD 0.12 billion, 15% share, CAGR 5.7%, administering over 3 million booster doses annually under public health programs.
• United Kingdom: Market size USD 0.1 billion, 13% share, CAGR 5.6%, distributing nearly 2.8 million booster doses annually to adolescents and adults.
• Japan: Market size USD 0.09 billion, 11% share, CAGR 5.8%, with 2.5 million booster doses administered annually under mandatory guidelines.
• Canada: Market size USD 0.07 billion, 9% share, CAGR 5.7%, delivering nearly 1.9 million booster doses annually, supported by strong adolescent coverage programs.

Pertussis Vaccine Market Regional Outlook

The Pertussis Vaccine Market demonstrates strong performance across all major regions, with Asia-Pacific leading in total immunization volume at 43% of the global share, followed by Africa at 26%, Europe at 18%, and North America at 13%. More than 116 million infants were vaccinated globally in 2023, with regional immunization programs ensuring consistent demand. High-income countries emphasize acellular vaccine coverage exceeding 95%, while low- and middle-income regions maintain strong demand for whole-cell formulations due to affordability. Each region reflects different adoption patterns, market dynamics, and investment opportunities, shaping the global Pertussis Vaccine Market Outlook for long-term growth and stability.

NORTH AMERICA

North America accounted for 13% of global pertussis vaccinations in 2023, with more than 15 million doses administered across the U.S., Canada, and Mexico. Acellular vaccines dominate, representing 98% of doses in the region. Over 95% of U.S. children under five are immunized, while 81% of adolescents received booster shots. Canada reported 89% infant coverage and nearly 70% maternal vaccination rates, while Mexico achieved 84% infant coverage. North America benefits from robust healthcare infrastructure and significant maternal immunization adoption, with more than 5 million maternal Tdap doses distributed in 2023. The Pertussis Vaccine Market Analysis identifies this region as a leader in advanced immunization programs.

North America Pertussis Vaccine Market Size is USD 1.1 billion with a 13% share and a CAGR of 6.3% projected during the forecast period.

North America - Major Dominant Countries

• United States: Market size USD 0.6 billion, 8% share, CAGR 6.4%, with over 12 million doses administered annually across infant, adolescent, and maternal programs.
• Canada: Market size USD 0.2 billion, 3% share, CAGR 6.2%, distributing nearly 2 million doses annually with 89% infant and 70% maternal vaccination rates.
• Mexico: Market size USD 0.15 billion, 2% share, CAGR 6.1%, delivering more than 1.5 million infant doses annually, achieving 84% immunization coverage.
• Cuba: Market size USD 0.07 billion, 1% share, CAGR 6.0%, with nearly 0.8 million doses distributed annually, reaching 88% infant coverage.
• Puerto Rico: Market size USD 0.05 billion, 1% share, CAGR 6.0%, administering 0.6 million doses annually, with 85% of infants immunized.

EUROPE

Europe represents 18% of the global pertussis vaccine market, with nearly 21 million doses administered in 2023. Acellular vaccines account for 97% of immunizations, making Europe one of the most advanced markets for pertussis coverage. Infant immunization coverage exceeds 93% across the region, while adolescent booster coverage averages 77%. Germany, France, and the UK lead demand, with combined consumption exceeding 12 million doses annually. Maternal immunization programs are expanding rapidly, with coverage levels reaching 58% across the EU. The Pertussis Vaccine Market Research Report highlights Europe’s dominance in acellular adoption and innovation in multi-antigen combination vaccines.

Europe Pertussis Vaccine Market Size is USD 1.5 billion with an 18% share and a CAGR of 6.4% projected during the forecast period.

Europe - Major Dominant Countries 

• Germany: Market size USD 0.4 billion, 5% share, CAGR 6.5%, with nearly 4 million doses administered annually and 95% infant coverage.
• France: Market size USD 0.3 billion, 4% share, CAGR 6.3%, distributing 3.2 million doses annually, including 70% adolescent booster coverage.
• United Kingdom: Market size USD 0.28 billion, 4% share, CAGR 6.2%, delivering 3 million doses annually, with maternal vaccination coverage exceeding 60%.
• Italy: Market size USD 0.2 billion, 3% share, CAGR 6.2%, with 2.5 million doses administered annually, ensuring 92% infant coverage.
• Spain: Market size USD 0.15 billion, 2% share, CAGR 6.1%, distributing 2 million doses annually with 90% infant immunization rates.

ASIA-PACIFIC

Asia-Pacific leads the Pertussis Vaccine Market with 43% of global share, accounting for more than 50 million doses administered in 2023. China, India, and Japan dominate, representing over 60% of the region’s demand. Infant vaccination coverage varies widely, from 95% in Japan to 82% in India. Maternal immunization programs are expanding, with 47% coverage in China and 39% in India. Acellular vaccines account for 62% of doses in Asia-Pacific, while whole-cell vaccines remain significant in South Asia. The Pertussis Vaccine Industry Analysis highlights Asia-Pacific as a region of strong growth due to large birth cohorts and increasing healthcare investments.

Asia-Pacific Pertussis Vaccine Market Size is USD 3.2 billion with a 43% share and a CAGR of 6.8% projected during the forecast period.

Asia - Major Dominant Countries 

• China: Market size USD 1.1 billion, 15% share, CAGR 6.9%, with 20 million doses administered annually and 47% maternal coverage.
• India: Market size USD 0.8 billion, 11% share, CAGR 6.6%, distributing 15 million doses annually, achieving 82% infant immunization rates.
• Japan: Market size USD 0.6 billion, 8% share, CAGR 6.5%, administering 6 million doses annually with 95% infant immunization coverage.
• South Korea: Market size USD 0.4 billion, 6% share, CAGR 6.4%, delivering 4.5 million doses annually, achieving 93% infant coverage.
• Australia: Market size USD 0.3 billion, 4% share, CAGR 6.3%, distributing 3 million doses annually with 91% infant immunization coverage.

MIDDLE EAST & AFRICA

The Middle East & Africa represents 26% of global pertussis vaccine demand, with nearly 30 million doses administered in 2023. Whole-cell vaccines dominate with 64% share, driven by affordability in low-income nations. Infant immunization coverage is improving, reaching 76% in sub-Saharan Africa and over 88% in Middle Eastern nations like Saudi Arabia. Maternal vaccination programs remain limited, with coverage below 20% across most of Africa. Nigeria, Egypt, and South Africa are key contributors, representing 54% of regional demand. The Pertussis Vaccine Market Outlook indicates strong opportunities for investment in infrastructure to boost acellular vaccine adoption.

Middle East & Africa Pertussis Vaccine Market Size is USD 1.9 billion with a 26% share and a CAGR of 6.1% projected during the forecast period.

Middle East and Africa - Major Dominant Countries

• Nigeria: Market size USD 0.5 billion, 7% share, CAGR 6.0%, administering 8 million doses annually with 72% infant immunization coverage.
• Egypt: Market size USD 0.4 billion, 5% share, CAGR 6.1%, distributing 6.5 million doses annually, achieving 84% infant vaccination rates.
• South Africa: Market size USD 0.3 billion, 4% share, CAGR 6.1%, delivering 4 million doses annually, with 81% infant immunization coverage.
• Saudi Arabia: Market size USD 0.35 billion, 5% share, CAGR 6.2%, administering 3.8 million doses annually with 89% infant coverage.
• Kenya: Market size USD 0.25 billion, 3% share, CAGR 6.0%, distributing 3 million doses annually, reaching 78% infant immunization rates.

List of Top Pertussis Vaccine Market Companies

• Chengdu Institute of Biological Products
• Minhai Biotechnology
• Wuhan Institute of Biological Products
• Sanofi Pasteur
• Mitsubishi Tanabe Pharma
• KM Biologics
• Walvax Biotechnology
• GSK

Top Two Companies with Highest Market Share

• Sanofi Pasteur: Holds the largest global share at 19%, supplying more than 25 million doses annually across 100+ countries, with strong dominance in North America and Europe for acellular vaccine formulations.
• GSK: Accounts for 17% of global share, distributing around 23 million doses annually, with leading positions in adolescent and maternal immunization programs across Europe, Asia-Pacific, and North America.

Investment Analysis and Opportunities

Investments in the Pertussis Vaccine Market are increasing due to rising birth cohorts and global immunization commitments. More than 116 million infants vaccinated annually ensure consistent demand. Around 21% of new investments target maternal immunization, with global maternal Tdap doses increasing from 9 million in 2020 to 12 million in 2023. Acellular vaccine production facilities expanded in Asia-Pacific, with China adding capacity for 8 million doses annually. Africa received $200 million in funding between 2021 and 2023 to strengthen immunization infrastructure, supporting broader coverage. Market Opportunities include new combination vaccine R&D, maternal programs, and local production expansion in emerging economies.

New Product Development

New product development in the Pertussis Vaccine Market emphasizes acellular formulations and maternal immunization programs. Around 33% of ongoing clinical trials focus on next-generation acellular vaccines, while 29% explore multi-antigen combinations. Between 2023 and 2024, Japan introduced two new combination vaccines covering DTaP and polio, distributed to nearly 1.2 million children. In the U.S., maternal booster formulations expanded, with 61% of pregnant women vaccinated in 2023 compared to 44% in 2018. China launched a locally developed acellular vaccine in 2023 with an annual capacity of 10 million doses. These innovations strengthen global coverage and improve safety standards.

Five Recent Developments 

• In 2023, Sanofi expanded acellular vaccine production capacity in France by 15%, ensuring supply of 5 million additional doses annually.
• GSK launched a new Tdap booster in North America in 2024, distributed to more than 3 million adolescents within its first year.
• China’s Walvax Biotechnology introduced a next-generation acellular vaccine in 2024, with capacity for 6 million doses annually targeting domestic and export markets.
• In 2025, India announced plans to replace 30% of whole-cell vaccines with acellular versions, covering an additional 4 million infants annually.
• Japan’s KM Biologics launched a clinical trial for a novel pertussis vaccine targeting improved durability, enrolling 1,200 participants in 2025.

Report Coverage of Pertussis Vaccine Market

The Pertussis Vaccine Market Report covers detailed industry insights, analyzing demand across more than 180 countries. It highlights immunization volumes exceeding 116 million infants annually, with 74% of global demand met by acellular vaccines and 26% by whole-cell formulations. Regional breakdowns emphasize Asia-Pacific leading with 43% share, followed by Africa at 26%, Europe at 18%, and North America at 13%. The report evaluates type-based segmentation, application trends in infants and adolescents, and maternal immunization programs. Competitive analysis identifies the top five global players controlling 61% of supply. The report also explores investments, new product development, and emerging market opportunities.

Pertussis Vaccine Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 5558.62068 Million in 2026
Market Size Value By	USD 7033.923200316 Million by 2035
Growth Rate	CAGR of 2.65% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Acellular Vaccines Whole-cell Vaccines By Application : 12 Months Below 12 Months Above
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample